Page 91 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Supplement
Risk of grade ≥ 3 toxicity, premature treatment termination and disease free survival for *c.2846A>T-carriers compared to non-carriers:
ref. 10, continuation
any toxicity
any 5-FU toxicity
diarrhoea neutropenia nausea/vomiting fatigue stomatitis/mucosi tis
dehydration leukopenia febrile neutropenia anorexia
pain thrombocytopeni a
premature treatment termination
dose modification disease free survival after 3 year
incide
nce
for
non-
carrie
rs 4
ORadj = 5.43 (95% 62% CI: 1.52-19.43) (S)
ORadj = 10.24 (95% 33% CI: 3.57-29.40) (S)
x 2.8 (S) 12% x 4.9 (S) 11% NS 5.0% NS 4.8% NS 4.1%
x 5.0 (S) 2.2% x 8.2 (S) 1.8% NS, trend for an 1.6% increase, p=0.08
NS 1.5% NS 0.8% x 55.5 (S) 0.2%
NS 26%
NS 74% NS 73%
When restricting the analysis to Caucasians, sex or treatment, the association between c.2846A>T and grade ≥ 3 5-FU toxicity remained significant. The association between c.2846A>T and grade ≥ 3 overall toxicity remained significant in the subgroups of Caucasians and males, but not in the subgroups of females, FOLFOX only and FOLFOX + cetuximab.
Other results:
- Because of its low frequency, a statistically significant association could not be demonstrated between *13 and either 5-FU or overall grade ≥ 3 toxicity (NS).
- The *2A/c.2846A>T-patient had a grade 5 adverse event. The patient was only able to receive one cycle of FOLFOX + cetuximab.
- The *1/274C-patient had no grade ≥ 3 adverse events.
table continues
89